Clinical Trials Logo

Clinical Trial Summary

The VA is the largest single provider of HIV care in the United States. The late 1990's have seen a revolution in the quality standards for this disease with the onset of Highly Active Antiretroviral Therapy (HAART) and other developments.


Clinical Trial Description

Background:

The VA is the largest single provider of HIV care in the United States. The late 1990's have seen a revolution in the quality standards for this disease with the onset of Highly Active Antiretroviral Therapy (HAART) and other developments.

Objectives:

Our purpose in this project is to develop a method for assessing quality in two important areas of HIV care - antiretroviral medications and opportunistic infection screening and prophylaxis - and explore the determinants of high quality care in order to suggest quality improvement strategies.

Methods:

The analysis has four parts. First, it will describe the level of adherence to the indicators in VA HIV patients nationwide and compare VA HIV patients to national benchmarks. Second, it will analyze facility and patient level predictors of adherence to indicators of quality of care and compare them with the predictors in the non VA population using staged logistic regressions. Third, it will seek to validate certain indicators (e.g. HAART therapy) against clinical outcomes like hospitalization and immune status. We will also model the clinical "price" that the VA pays in suboptimal clinical outcomes as a result of current performance levels. Fourth, we will compare the performance of the facilities after one year of an intensive targeted indicator-specific feedback group versus those receiving aggregate data only.

Status:

Data analysis. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00012701
Study type Observational
Source VA Office of Research and Development
Contact
Status Completed
Phase N/A
Completion date June 2003

See also
  Status Clinical Trial Phase
Completed NCT00639145 - Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
Completed NCT01152684 - Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border
Completed NCT01957748 - CCTG 594: Engagement and Retention in Care for HIV+ N/A
Completed NCT01818258 - IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children Phase 4
Withdrawn NCT03660722 - Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects N/A
Completed NCT01793467 - Transplantation and the Use of Raltegravir in HIV-Infected Patients N/A
Completed NCT02938377 - Alcohol Research Consortium in HIV-Intervention Research Arm Phase 4
Completed NCT01898754 - Oligonucleotide Ligation Assay (OLA) Resistance Study N/A
Active, not recruiting NCT01365065 - Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy Phase 2
Completed NCT00106795 - Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS N/A
Not yet recruiting NCT02404233 - Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Phase 4
Completed NCT01154543 - Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes N/A
Completed NCT01154556 - RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice N/A
Completed NCT00857350 - The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment N/A
Recruiting NCT01875588 - Thinking and Memory Problems in People With HIV
Completed NCT01941121 - CCTG 593: Testing and Linkage to Care N/A
Terminated NCT01904201 - Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People N/A
Enrolling by invitation NCT00941889 - The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata N/A
Completed NCT03531749 - Antioxidant in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate N/A
Completed NCT02935296 - Integrated Treatment and Prevention for People Who Inject Drugs Phase 3